Gapping up
In reaction to strong earnings/guidance:
- SFIX +12.9% (also appointed Elizabeth Spaulding as President), CDMO +9.4%, MDB +7.4%, AZO +4.9%, PHR +4.1%, MTN +2.3% (also detailed planned capital investments for CY20), CMD +2.1%
M&A news:
- NLOK +4.3% (said to have attracted deal interest from several parties, including Intel's (INTC) McAfee, according to the WSJ)
Other news:
- SUPN +10.1% (provided update regarding Phase III study of SPN-810 for Impulsive Aggression in patients with ADHD)
- CMRX +7.9% (presents data relating to dociparstat sodium program at ASH)
- PSN +5.1% (won "prime position" on DISA's $7.5 bln SETI contract)
- SNY +4% (says pivotal Phase 3 open-label, single-arm trial evaluating the safety and efficacy of sutimlimab in people with primary cold agglutinin disease met its primary and secondary endpoints)
- EDIT +1.9% (reported in vivo proof-of-concept data for EDIT-301)
- ENOB +1.6% (announces that important scientific findings reveal an innovative approach to potentially treat and cure Hepatitis B)
- GOLD +1.2% (to sell their aggregate 90% interest in the Massawa project in Senegal to Teranga Gold Corporation for total consideration of up to $430 million)
- ENB +1% (increases quarterly dividend by 9.8% to $0.81 per share)
- AUPH +0.8% (prices offering of 11,115,165 shares of common stock at $15.00 per share)
Analyst comments:
- RDFN +3.8% (upgraded to Buy at DA Davidson)